GALNT14 and hepatocellular carcinoma: In addition to HCC, the GALNT14 SNP has been shown to predict progression-free survival (PFS), overall survival (OS), and response to chemotherapy in several types of gastrointestinal cancers, including cholangiocarcinoma, colorectal cancer, gastric cancer, esophageal cancer, and pancreatic ductal adenocarcinoma [12].